-
Mashup Score: 0FDA approves teplizumab: a milestone in type 1 diabetes - 1 year(s) ago
New therapies come slowly for type 1 diabetes, so the approval of teplizumab by the USA Food and Drug Administration (FDA) marks a milestone. The drug itself, a humanised anti-CD3 monoclonal antibody, delays clinical type 1 diabetes in at-risk individuals and is the first approved disease-modifying drug for type 1 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet
-
Mashup Score: 2FDA approves teplizumab: a milestone in type 1 diabetes - 1 year(s) ago
New therapies come slowly for type 1 diabetes, so the approval of teplizumab by the USA Food and Drug Administration (FDA) marks a milestone. The drug itself, a humanised anti-CD3 monoclonal antibody, delays clinical type 1 diabetes in at-risk individuals and is the first approved disease-modifying drug for type 1 diabetes.
Categories: Endocrinology, Latest HeadlinesTweet-
New—FDA approves #teplizumab: a milestone in type 1 #diabetes https://t.co/g6S7XuCkIm #T1D #FREE to read with registration (also FREE) https://t.co/B5vX3DYLkL
-
-
Mashup Score: 0Teplizumab Approved by FDA to Delay Type 1 Diabetes - 1 year(s) ago
The biologic is the first drug that aims to delay the diagnosis of type 1 diabetes.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
#Teplizumab Approved by #FDA to Delay Type 1 #Diabetes https://t.co/C1DYK6NolX https://t.co/4s8wrMt94W
-
-
Mashup Score: 0
A user fee goal date of August 17, 2022 has been assigned to teplizumab.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
The resubmitted BLA for #teplizumab is considered a complete, class 2 response to the July 2021 action letter and was assigned a user fee goal date in August 2022. https://t.co/VKMLuUVWWh
-
-
Mashup Score: 0
A user fee goal date of August 17, 2022 has been assigned to teplizumab.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
The #FDA has accepted the resubmitted BLA for #teplizumab for the delay of clinical type 1 #diabetes. https://t.co/bn2xeoxFlE
-
-
Mashup Score: 0CRL Issued for Provention Bio's T1D Drug Teplizumab - 3 year(s) ago
The FDA issued a Complete Response Letter, halting Provention Bio’s type 1 diabetes prevention drug.
Source: AJMCCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
CRL Issued for Provention Bio's T1D Drug #Teplizumab: https://t.co/uhMn3ni3Tc https://t.co/vvpkOD3LS1
-
-
Mashup Score: 0
FDA cites pharmacokinetic comparability considerations remained outstanding, while no clinical deficiencies on efficacy and safety were reported.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
The #FDA has issued a complete response letter for #teplizumab, in delay of #T1D, citing study data failed to show pharmacokinetic comparability. https://t.co/49KTu5s7hh
-
-
Mashup Score: 0Elena A Christofides, MD: Perspectives on Risk Factors, Care for Type 1 Diabetes Patients - 3 year(s) ago
In part 1 of a Q&A, Elena Christofides, MD highlights important discussions surrounding ADA 2021, including cardiometabolic medicine and risk factors for T1D.
Source: HCPLive®Categories: General Medicine News, Latest HeadlinesTweet-
Check out a recent Q&A with Elena Christofides, MD surrounding topics discussed at #ADA2021 including #teplizumab and #semaglutide. https://t.co/R5WE8mMsYx
-
-
Mashup Score: 0ADA updates standards of care to reflect new teplizumab, HF data - 3 year(s) ago
The American Diabetes Association issued updates to the 2021 Standards of Medical Care in Diabetes to reflect new data on the immunotherapy teplizumab for type 1 diabetes and heart failure benefits seen with SGLT2 inhibitors.The updates, in annotations to the Living Standards of Care, also include new information on the medications’ effects on patients with chronic kidney disease.
Source: www.healio.comCategories: Endocrinology, Latest HeadlinesTweet-
ICYMI: "There have been so many exciting advancements in the field of #diabetes, and that is why we are publishing more frequent updates to the Standards of Care." @AmDiabetesAssn #teplizumab for #T1D #HF https://t.co/mcBif9W6eG
-
-
Mashup Score: 1ADA updates standards of care to reflect new teplizumab, HF data - 3 year(s) ago
The American Diabetes Association issued updates to the 2021 Standards of Medical Care in Diabetes to reflect new data on the immunotherapy teplizumab for type 1 diabetes and heart failure benefits seen with SGLT2 inhibitors.The updates, in annotations to the Living Standards of Care, also include new information on the medications’ effects on patients with chronic kidney disease.
Source: www.healio.comCategories: General Medicine News, Latest HeadlinesTweet-
The @AmDiabetesAssn updated its Living Standards of Care to reflect new data from trials for #teplizumab for #T1D and #HF and renal benefits seen with several SGLT2 inhibitors in type 2 #diabetes. https://t.co/jpVmN2xdb5
-
The @AmDiabetesAssn updated its Living Standards of Care to reflect new data from trials for #teplizumab for #T1D and #HF and renal benefits seen with several SGLT2 inhibitors in type 2 #diabetes. https://t.co/mcBif9EuQ6
-
Online—FDA approves #teplizumab: a milestone in type 1 #diabetes https://t.co/g6S7XuTnKm #T1D #FREE to read with registration (also FREE)